rethinkPeptides Search
Menu
Study breakdown

Liraglutide vs Calorie Restriction for Reducing Fat Inside the Pancreas

evidence
The takeaway

A pilot study comparing liraglutide to calorie restriction for reducing intrapancreatic fat deposition in people with obesity, exploring whether fat reduction in the pancreas improves metabolic health.

24-week pancreatic fat comparison

Liraglutide vs calorie restriction for intrapancreatic fat reduction in obesity

What the researchers found

The pilot study compared changes in pancreatic fat fraction between calorie restriction and liraglutide over 24 weeks, with secondary analysis of weight, liver fat, and glycemic parameters.

Why it matters

Pancreatic fat is an emerging target in diabetes prevention. If GLP-1 drugs reduce pancreatic fat specifically, it could protect insulin-producing cells and prevent diabetes progression.

How the study worked

Prospective nonrandomized 24-week study; CRD vs liraglutide in obesity; primary endpoint: pancreatic fat fraction by MRI.

What this study cannot tell us

Pilot study with small sample; nonrandomized design introduces bias; 24 weeks may be insufficient for maximum fat reduction; liraglutide vs newer GLP-1 drugs not compared.

How to read the evidence

Pilot nonrandomized prospective study — generates hypotheses but limited by small size and lack of randomization.

When this study was published

Published in 2026, addressing the emerging importance of organ-specific fat depots in metabolic disease.

The bigger picture

This shifts focus from visible body fat to invisible organ fat — recognizing that fat inside the pancreas may be more important for diabetes risk than overall body weight.

Questions still open

  • Does reducing intrapancreatic fat actually improve beta-cell function and insulin production?
  • Would semaglutide or tirzepatide reduce pancreatic fat more effectively than liraglutide?

Common questions

Why does fat in the pancreas matter?
Fat accumulation inside the pancreas may directly impair the insulin-producing beta cells, contributing to diabetes development. Reducing this hidden fat could help protect pancreatic function.
Can GLP-1 drugs reduce pancreatic fat specifically?
This pilot study tested that question by comparing liraglutide to dieting. GLP-1 drugs cause weight loss and may also specifically reduce fat in metabolically important organs like the pancreas and liver.

Read the original research

Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.

Obesity (Silver Spring, Md.)

Citation

Cheng, Haiyan; Jiang, Xiao; Zhu, Xiaowei; Zhu, Xiaowen; Li, Chenxi; Cao, Mengjiao; Zhou, Qunyan; Deng, Shukun; Wu, Wenjun. (2026). Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.. Obesity (Silver Spring, Md.). https://doi.org/10.1002/oby.70153